Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs.

Roon, K. I.; Sandor, P. S.; Schoonman, G. G.; Lamers, F. P.; Schoenen, Jean; Ferrari, M. D.; van Dijk, J. G.

doi:10.1046/j.1468-2982.1999.1910880.x

No full text

Article (Scientific journals)

Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs.

Roon, K. I.; Sandor, P. S.; Schoonman, G. G. et al.

1999 • In Cephalalgia, 19 (10), p. 880-5

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/24213

DOI
10.1046/j.1468-2982.1999.1910880.x

PubMed
10668107

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Adolescent; Adult; Cerebral Cortex/drug effects/physiology; Evoked Potentials, Auditory/drug effects; Female; Humans; Indoles/pharmacology; Male; Oxazoles/pharmacology; Oxazolidinones; Piperidines/pharmacology; Reproducibility of Results; Sample Size; Serotonin Agonists/pharmacology; Tryptamines

Abstract :

[en] Because the "intensity dependence" of cortical auditory evoked potentials (IDAP) is under serotonergic control, it can be used to assess central antimigraine effects of 5HT1B/1D agonists. We measured IDAP before and 2 h after naratriptan (5 mg, n = 19) and zolmitriptan (5 mg, n = 19) in healthy volunteers. IDAP was expressed as the amplitude-stimulus intensity function ("ASF slope"). Naratriptan tended to increase ASF slope (mean difference 0.23 +/- 0.62 microV/10 dB, p = 0.06) while zolmitriptan (0.08 +/- 0.95 microV/10 dB, p = 0.35) did not. We assessed the suitability of IDAP for measuring central antimigraine drug effects using repeatability data (see companion paper). We calculated the trade-off between the size of the expected drug effects (ASF slope difference) and the necessary sample size. Because of poor repeatability 36 to 80 subjects are required to detect ASF slope changes in the 0.25-0.5 microV/10 dB range. These data can be used to design trials using IDAP.

Disciplines :

Neurology
Neurosciences & behavior

Author, co-author :

Roon, K. I.

Sandor, P. S.

Schoonman, G. G.

Lamers, F. P.

Schoenen, Jean ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Neuro-anatomie

Ferrari, M. D.

van Dijk, J. G.

Language :

English

Title :

Auditory evoked potentials in the assessment of central nervous system effects of antimigraine drugs.

Publication date :

1999

Journal title :

Cephalalgia

ISSN :

0333-1024

eISSN :

1468-2982

Publisher :

Blackwell Science, Osney Mead Oxford, United Kingdom

Volume :

Issue :

Pages :

880-5

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 28 September 2009

Statistics

Number of views

71 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

D'Andrea G, Cananzi AR, Morra M, Zamberlan F, Milone FF, Grunfeld S, et al. Platelet glycine, glutamate and aspertate in primary headache. Cephalalgia 1991;11:197-200
Ferrari MD, Odink J, Bos KD, Malessy MJA, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990;40:1582-6
Martinez F, Castillo J, Rodriguez JR, Leira R, Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia 1993;13:89-93
Hay KM, Mortimer MJ, Barker DC. 1044 woman with migraine: the effect of environmental stimuli. Headache 1994;34:166-8
Afra J, Proietti-Cecchini A, De Pasqua V, Albert A, Schoenen J. Visual evoked potentials during long periods of pattern-reversal stimulation in migraine. Brain 1998;121:233-41
Wray SH, Mijovic-Prelec D, Kosslyn SM. Visual processing in migraineurs. Brain 1995;118:25-35
Schoenen J. Clinical neurophysiology studies in headache: a review of data and pathophysiological hints. Funct Neurol 1992;7:191-204
van Dijk JG, Haan J, Ferrari MD. Photic stimulation and the diagnosis of migraine. Headache Quarterly 1992;3:387-97
Schoenen J. Clinical neurophysiology of headache. Anonymous advances in headache. 15th ed. Neurol Clin 1997:85-105
Visser WH, Klein KB, Cox RC, Jones D, Ferrari MD. 311C90, a new central and peripherally acting 5HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996;46:522-6
Elkind A, Laurenza A, Austin R, et al. Efficacy and tolerability of naratriptan tablets in the treatment of migraine: results of a double-blind, placebo-controlled, parallel-group trial. [Abstract]. Cephalalgia 1997;17:419
Humphrey PPA, Feniuk W. Mode of action of the antimigraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-6
Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993;14:129-33
Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-11
Goadsby PJ. Pathophysiology of migraine: a disease of the brain. In: Goadsby PJ, Silberstein SD, editors: Headache. Boston: Butterworth-Heineman, 1997: 5-25
Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996;67:355-9
Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the meninges. Br J Pharmacol 1992;106:409-15
Pascual J, Arco del C, Romon T, Omlo del E, Castro E, Pazos A. Autoradiographic distribution of [3H]sumatriptan-binding sites in post-mortem human brain. Cephalalgia 1996;16:317-22
Schoenen J, Klein KB, Sweet RM. for the Multinational Oral 311C and Sumatriptan Comparative Study Group. The CNS adverse event profile of 311C90 and sumatriptan appear identical [Abstract]: Eur J Neurol 1996; 3 Suppl 5:153
Sullivan JT, Preston KL, Testa MP, Busch MP, Jasinski DR. Psychoactivity and abuse potentials of sumatriptan. Clin Pharmacol Ther 1992;52:635-42
Edmeads J, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/D agonist. International clinical experience based on >3000 subjects treated with zolmitriptan. Cephalalgia 1997;17 Suppl 18:41-52
Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as a indicator of central serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 1993;33:173-87
Wang W, Timsit-Berthier M, Schoenen J. Intensity dependence of auditory evoked potentials is pronounced in migraine: an indication of cortical potentiation and low serotonergic neurotransmission? Neurology 1996;46:1404-9
Goadsby PJ, Knight YE. Direct evidence for central site of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997;17:153-8
Martin GR. Inhibition of the trigemino-vascular system with 5HT1D agonist drugs: selectively targeting additional sites of action. Eur Neurol 1996;36 Suppl 2:13-8
Proietti-Cecchini A, Schoenen J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 1997;17:849-54
Connor HE, Feniuk W, Beattie DT, North PC, Oxford AW, Sayner DA, et al. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia 1997;17:145-52
Knight YE, Goadsby P. Naratrptan inhibits central trigeminal neurons after systemic administration by a 5HT1B/D receptor in cat [Abstract]. Cephalalgia 1997;17:403
Lipton RB, Stewart WF. Clinical applications of zolmitriptan (Zomig, 311C90). Cephalalgia 1997;17 Suppl 18:53-9
Sándor PS, Roon KI, Ferrari MD, van Dijk JG, Schoenen J. Repeatability of the intensity dependence of cortical auditory evoked potentials in the assessment of cortical information processing. Cephalalgia 1999;19:873-9
Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;8:307-10
Pocock SJ. Clinical trials. A practical approach. Chichester: John Wiley 1983
Goadsby PJ, Knight YE. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxytryptamine (5HT1B/1D) receptors. Br J Pharmacol 1997;122:918-22